Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.
In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity ...
Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving ...
Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for ...
They say GLP-1s for weight loss is a shortcut — it’s not. It’s science,” she says during the spot. “After kids, it’s the ...
While the TrumpRx deals only cover Lilly and Novo for now, the agreements are good for any cardiometabolic biotechs waiting ...
Health and Me on MSN
WHO Issues First Guidance On Obesity Drugs — GLP-1 Drugs Get the Green Light
WHO has issued its first-ever guidance recommending GLP-1 drugs for long-term obesity management, marking a major shift from ...
Smartphones are widely owned by children in America, with a Pew Research Center survey finding that 95% of teens ages 13-17 ...
The WHO has officially recommended GLP-1 drugs, such as semaglutide, for treating obesity in adults at high risk of weight-related complications. Citing strong evidence for significant weight loss and ...
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Democrats aim to de-politicize ACIP A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback